Home Blog Page 297

Bybit Launches SpaceX-Themed Token Buzz: $100K Prize Pool

By
Advertorial Desk
-

DUBAI, UAE, June 16, 2026 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, has announced the latest round of Token Buzz, its trading competition series, with SpaceX perpetual contracts as the featured token. The limited-time event ends on June 30, 2026, with $100,000 in prizes to be distributed among the top-performing traders.

Following its NASDAQ listing on 12 June, 2026, SpaceX perpetuals are now live on Bybit. The new round of Token Buzz allows Bybit users to center their trading ambition around one of the most groundbreaking innovators of global significance across finance, space exploration, and AI technology.

How it works:

  • Rankings are determined by cumulative eligible SpaceX perpetual volume over 15 days.
  • The minimum qualifier is 5,000 USDT in total volume.
  • The top traders split the prize pool, which grows in tiers as community trading volume hits milestones. The larger the community trades, the larger the final pool.

Traders are ranked according to eligible USDT-equivalent volume, tracked transparently on the leaderboard. Interested participants may register and begin trading SpaceX perpetuals.

The previous round of Bybit’s Token Buzz featured HYPE, a pioneering asset in DeFi, The new edition enables traders to engage with real-world possibilities. SpaceX perpetual contracts on Bybit offer institutional-grade liquidity and daily price discovery tied to one of the most imaginative enterprises of the times.

Terms and conditions apply. For details of eligibility, potential restrictions, and other information, users may visit: Token Buzz: Trade SpaceX. Win your share of up to $100,000

#Bybit  / #NewFinancialPlatform

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

METALIGHT (02605.HK): Co-Authored Research Paper Accepted to the Applied Data Science Track of KDD 2026

By
Advertorial Desk
-

HONG KONG, June 16, 2026 /PRNewswire/ — MetaLight Inc. (“MetaLight” or the “Company”; Stock Code: 02605.HK), a public transit information service provider powered by time series data analytics and AI technology, today announced that a peer-reviewed research paper co-authored with Peking University and other institutions has been accepted to the Applied Data Science (ADS) Track of KDD 2026. Titled “A Data-driven Route Segmentation Framework for Time-of-Arrival Estimation Service,” the paper’s authors are affiliated with Peking University, MetaLight HK Limited (a member of the Group) and other institutions, and its first author is from Peking University; the Company’s Chairman and CEO, Dr. Sun Xi, is a co-author. It addresses route segmentation — a previously underexplored step in bus arrival-time estimation (ETA); the Company’s team, drawing on its Chelaile platform, provided the real-world data and the online deployment environment for the work.

KDD (the ACM SIGKDD Conference on Knowledge Discovery and Data Mining), organized by ACM SIGKDD, is rated a Class A recommended conference by the China Computer Federation (CCF) and will be held in Jeju, South Korea, from August 9 to 13, 2026. Accepted in the track’s second review cycle (Cycle Two), the paper will be included in the proceedings and presented at the conference by its authors.

In bus ETA, a route is typically divided into segments using predefined markers such as intersections, with traffic data aggregated accordingly. Coarse segmentation can blur fine-grained differences in traffic conditions along the same route and constrain prediction accuracy. The research instead draws on large-scale, fine-grained vehicle trajectory data to segment routes so that each segment corresponds to a relatively stable traffic regime, characterizing real traffic variation along a route more precisely.

In offline evaluations covering over a thousand routes and more than a million trajectories, the method outperformed commonly used route-segmentation strategies. In a one-week online evaluation on the Chelaile service across two cities, it reduced storage usage by approximately 90% and CPU usage by approximately 25% at comparable prediction accuracy.

Prior ETA research has focused largely on the prediction model itself, with less attention to how a route is segmented and how its data is organized; this work indicates that this step is just as important to prediction accuracy and operational efficiency. In the Company’s bus ETA service, the approach has materially lowered storage and compute requirements at comparable accuracy, making the large-scale online service lighter to run.

Beyond the work accepted to KDD 2026, MetaLight has in recent years also co-authored papers in temporal point processes (with Renmin University of China, Shanghai Jiao Tong University and Fudan University, accepted to AAAI 2026) and model merging (with Shanghai Jiao Tong University and the Shanghai Artificial Intelligence Laboratory, accepted to IJCNN 2025).

A representative of MetaLight said, “This work benefited from the collaboration of our team with Peking University and other partners. We care more about whether technology solves concrete problems in real-world settings, and we also hope to foster an internal culture of active learning and continuous evolution; we will keep building our foundational technology steadily, through long-term investment and collaboration.”

About MetaLight

MetaLight Inc. (Stock Code: 02605.HK) is a public transit information service provider powered by time series data analytics and AI technology. With a focus on time series data foundation models, the Company has built a technology stack with its core comprising an AI Model Building Platform and AI model libraries for three industry verticals: public bus, renewable energy and industrial internet, integrating capabilities in data access, pre-processing, labeling, AI model training and foundation model adaptation. Based on this technology stack, the Company operates the Chelaile real-time public transit information platform, providing commuters with services including real-time bus arrival predictions, vehicle location tracking and travel route planning, while also offering public transit analytics platforms and data technology services to transport operators. According to CIC data as of December 31, 2024, Chelaile is the largest real-time public transit information platform in China by city coverage. As of December 31, 2025, it covered 488 cities and towns nationwide with approximately 334 million cumulative users, committed to making public transit more convenient and efficient. For more information, please visit www.metalight.ai.

Forward-Looking Statements

In addition to statements of historical fact, this press release contains forward-looking statements relating to the Company’s business outlook, estimates of financial performance, forecast business plans, development strategies and projections of anticipated trends in our industry. Forward-looking statements can generally be identified by the use of forward-looking terminology such as “may,” “might,” “can,” “could,” “will,” “would,” “expect,” “believe,” “continue,” “estimate,” “anticipate,” “forecast,” “intend,” “plan,” “seek” or “timetable.” Such forward-looking statements are based on the information available to the Company and the outlook as at the time of publication of this press release. Such forward-looking statements are based on certain projections, assumptions and premises, some of which involve subjective factors or factors beyond our control. Such forward-looking statements may prove to be inaccurate and may not materialize in the future. Such forward-looking statements involve a number of risks and uncertainties. In view of the risks and uncertainties, forward-looking statements contained in this press release should not be construed as representations by the Board or the Company that such plans and objectives will be achieved, and investors should not place undue reliance on such statements. Except as required by law, neither the Company, its Board, employees nor agents assume any obligation to publicly release any revisions, corrections or updates to the forward-looking statements contained in this press release to reflect events or circumstances occurring after the date of this press release or unanticipated events, nor do they assume any liability for any losses arising from the failure to realize or inaccuracy of any forward-looking statements.

Investor and Media Inquiries

MetaLight Inc.
Investor Relations
Email: ir@metalight.ai

DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES

By
Advertorial Desk
-
  • Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia
  • 500,000-1 million people are estimated to be living with FSGS in the territories[1]
  • Dimerix eligible to receive upfront and potential success-based milestone payments of up to ~AU$481[2] million, plus royalties
    • US$10 million (~AU$14.1 million2) upfront payment
    • Up to US$330 million (~AU$467 million2) in potential milestone payments
    • Tiered royalties on net sales
  • Everest is the fifth license deal executed for DMX-200 following the license deals with Advanz Pharma (announced October 2023)[3], Taiba Rare (announced May 2024)[4], Fuso Pharmaceutical Industries (announced 7 January 2025)[5], and Amicus Therapeutics (announced 1 May 2025, now BioMarin)[6]; with over AU$65 million having been received prior to the Everest transaction
  • Collectively across the 5 transactions, Dimerix may be eligible to receive up to ~AU$1.9 billion[7] in aggregate total upfront and potential milestone payments, plus additional royalties on net sales
  • DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and serious kidney disease with no approved therapies across these regions
  • The ACTION3 Phase 3 clinical trial is fully recruited, with patients enrolled across 21 countries, including Chinese mainland, Hong Kong SAR, Taiwan region, Thailand and Malaysia
  • Everest will leverage its specialty kidney disease expertise and commercial platform to register and commercialise DMX-200, offering greater patient access to the growing Asian markets
  • Dimerix retains all rights to DMX-200 in all other unlicensed territories

MELBOURNE, Australia, June 16, 2026 /PRNewswire/ — Dimerix Limited (ASX: DXB, “Dimerix”) today announced that it has entered into an exclusive license agreement with Everest Medicines for the commercialisation of Dimerix’s Phase 3 drug candidate DMX-200 for all indications including FSGS, in Greater China (Chinese mainland, Hong Kong SAR, Macao SAR and Taiwan region), South Korea and certain Southeast Asian countries (Singapore, Malaysia, Thailand, Indonesia, Vietnam and Philippines). Dimerix retains all rights to commercialise DMX-200 in all territories other than those already exclusively licensed.

DMX-200 is a small molecule inhibitor of the chemokine receptor 2 (CCR2) under development in a pivotal, Phase 3 study, ACTION3, for the treatment of Focal Segmental Glomerulosclerosis (FSGS), a rare and serious kidney disease. The ACTION3 Phase 3 clinical trial adult cohort is fully recruited, with 333 patients, including patients in the licensed territories.

In early 2024, Dimerix reported positive interim results from the ACTION3 trial in FSGS, showing DMX-200 was performing better than placebo in reducing proteinuria at that time.[8] There have been no safety concerns to date following 8 reviews by the independent data monitoring committee, the most recent in June 2026. In April 2026, an external statistical blinded review of ACTION3 data achieved its objective by confirming that the study remains appropriately statistically powered (>90%) to demonstrate a treatment effect for the primary study endpoint of proteinuria; meaning that if DMX-200 continues to reduce proteinuria in trial patients as anticipated, then there is a >90% chance that the study will successfully show a statistically significant proteinuria treatment effect at the trial’s conclusion.[9]

“We are delighted to establish this partnership with Everest Medicines, a company with strong rare renal disease expertise and a proven track record in commercialising in Greater China, South Korea and certain Southeast Asian countries. Importantly, this collaboration significantly expands the potential reach of DMX-200 into a large and underserved patient population. Everest is well positioned to maximise the opportunity in the licensed regions, while allowing Dimerix to retain focus on progressing our global registrational program, delivering value for shareholders and providing real hope for patients with FSGS across the globe in need of treatment options.”

Dr Nina Webster, CEO & Managing Director, Dimerix

“This collaboration with Dimerix marks an important step in advancing our strategic focus in kidney disease and further strengthening our innovative renal portfolio. Patients with FSGS in China have long faced significant unmet medical needs due to the lack of targeted treatment options. The positive interim results from the global pivotal Phase 3 study of DMX-200 underscore its potential to offer a meaningful new therapy for these patients.

Leveraging our proven expertise in clinical development and commercialisation, we are committed to accelerating access to DMX-200 in China and beyond and exploring other glomerulopathies. We look forward to working closely with Dimerix to bring this innovative therapy to more patients in need.”

Yifang Wu, Chairman of the Board, Everest Medicines

Dimerix will continue to fund and execute the ACTION3 study, and Everest will be responsible for supporting submission and maintenance of the regulatory dossier in the licensed territories, as well as all costs of commercialisation activities. Everest and Dimerix will form a Joint Steering Committee to align the development and commercialisation of DMX-200 in FSGS in the licensed territories. The agreement otherwise contains terms common for an arrangement of this kind.

In exchange for these rights, Dimerix is to receive a US$10 million (~AU$14.1 million[2]) upfront payment within 45 business days of execution. In total, Dimerix is eligible to receive potential success-based development and regulatory milestones payments of up to US$30 million (~AU$42.4 million[2]) and commercial milestone payments of up to US$300 million (~AU$424.4 million[2]), with tiered royalties on DMX-200 net sales of between 10-15% in Greater China, South Korea, and certain Southeast Asian countries. Note that milestone payments are not broken down further, as that can negatively influence negotiations of contracts in other territories currently under discussion, and thus remains commercial in confidence. All contracted financial terms are denominated in U.S. dollars.

Authorised for lodgement with ASX by the Board of Dimerix.

—END— 

About ACTION3 Phase 3 Study
The Phase 3 study, which is titled “Angiotensin II Type 1 Receptor (AT1R) & Chemokine Receptor 2 (CCR2) Targets for Inflammatory Nephrosis”, or ACTION3 for short, is a pivotal (Phase 3), multi-centre, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with FSGS who are receiving a stable dose of an angiotensin II receptor blocker (ARB). Once the ARB dose is stable, patients will be randomized to receive either DMX-200 (120 mg capsule twice daily) or placebo.

The single Phase 3 trial in FSGS patients has two interim analysis points built in that are designed to capture evidence of proteinuria and kidney function (eGFR slope) during the trial, aimed at generating sufficient evidence to support marketing approval. Further information about the study can be found on ClinicalTrials.gov (Study Identifier: NCT05183646) or Australian New Zealand Clinical Trials Registry (ANZCTR) (Study Identifier ACTRN12622000066785).

About DMX-200
DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. DMX-200 is protected by granted patents in various territories until 2032, with patent applications submitted globally that may extend patent protection to 2042, in addition to Orphan Drug Designation granted in the United States, Europe, UK and Japan[10].

About FSGS
FSGS is a serious kidney disorder characterised by progressive scarring (sclerosis) in parts of the glomeruli—the kidney’s filtering units. This scarring leads to proteinuria, progressive loss of kidney function, and often end-stage renal disease. The pathogenesis of FSGS is increasingly understood to have an inflammatory component, with monocyte and macrophage activation contributing to glomerular injury. In China, 500,000 to 1 million people[1] are estimated to be living with FSGS, including both adults and children. Management relies on non-specific immunosuppressive and supportive therapies in most countries around the world. In patients with progressive or treatment-resistant FSGS, the time from diagnosis to end-stage kidney disease can be as short as five years. Even among those with FSGS who undergo kidney transplantation, disease recurrence occurs in up to 60% of cases,[11] underscoring the urgent need for new disease-modifying treatments.

About Dimerix Limited
Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including kidney diseases. Dimerix is currently focused on developing its proprietary Phase 3 product candidate DMX-200, for Focal Segmental Glomerulosclerosis (FSGS) kidney disease. DMX-200 was identified using Dimerix’ proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform, enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. For more information, please visit the company’s website at www.dimerix.com and follow on X and LinkedIn.

About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercialising innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.

The Company’s therapeutic areas of focus include CKM (cardiovascular, kidney, and metabolic), autoimmune, ophthalmology and critical care. Everest Medicines has developed a fully integrated commercialisation platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website at www.everestmedicines.com.

Dimerix Forward Looking Statement
This release includes forward-looking statements that are subject to risks and uncertainties. Although management believes that the expectations reflected in the forward-looking statements are reasonable at this time, Dimerix can give no assurance that these expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, results of clinical trials, contractual risks, risks associated with patent protection, future capital needs or other general risks or factors, including but not limited to those factors outlined in the most recent Dimerix Limited Annual Report.

References

[1] Yang Y, Zhang Z, Zhuo L, Chen DP, Li WG. (2018) The Spectrum of Biopsy-Proven Glomerular Disease in China: A Systematic Review. Chin Med J (Engl), 131(6):731–735; and Du X, Xiao D, Ao C, Zhang Y, Xuan J. Disease Burden of IgA Nephropathy in China. ISPOR Europe 2021. (poster/presentation)

[2] Based on XE rate of 1 USD = 1.41612 AUD as at 15 June 2026

[3] ASX release 5 October 2023

[4] ASX release 27 May 2024

[5] ASX release 7 January 2025

[6] ASX release 01 May 2025

[7] Based on XE exchange rates & further terms outlined in ASX Announcements on 5 October 2023, 27 May 2024, 07 January 2025, 01 May 2025; and 16 June 2026

[8] ASX release 11 March 2024; Predictive Power statistical model, using industry standard as set by the independent renal biostatistician consultant for Dimerix; Interim analysis data does not guarantee a statistically significant outcome at the end of the trial

[9] ASX release 28 April 2026

[10] ASX releases: 14 December 2015, 21 November 2018, 07 June 2021, 30 September 2025

[11] Front. Immunol., (July 2019) https://doi.org/10.3389/fimmu.2019.01669

 

ZTO Express Announces Results of Annual General Meeting

By
Advertorial Desk
-

SHANGHAI, June 16, 2026 /PRNewswire/ — ZTO Express (Cayman) Inc. (NYSE: ZTO and HKEX: 2057), a leading and fast-growing express delivery company in China (“ZTO” or the “Company”), today announced that each of the following proposed resolutions submitted for shareholder approval has been adopted as an ordinary resolution at its annual general meeting of shareholders held in Hong Kong today:  

1.

to receive and consider the audited consolidated financial statements of the Company and the reports of the directors and auditor of the Company for the year ended December 31, 2025;

2.

to re-elect Mr. Hongqun HU as an executive director of the Company, subject to his earlier resignation or removal;

3.

to re-elect Mr. Xing LIU as a non-executive director of the Company, subject to his earlier resignation or removal;

4.

to authorize the Board to fix the remuneration of the directors;

5.

to re-appoint Deloitte Touche Tohmatsu and Deloitte Touche Tohmatsu Certified Public Accountants LLP as auditors of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorize the board to fix their remuneration for the year ending December 31, 2026;

6.

to grant a general mandate to the directors to issue, allot, and deal with additional Class A ordinary shares of the Company (including any sale or transfer of treasury shares out of the treasury) not exceeding 20% of the total number of issued and outstanding shares of the Company (excluding any treasury shares) as at the date of passing of this resolution.

7.

to grant a general mandate to the directors to repurchase Class A ordinary shares of the Company not exceeding 10% of the total number of issued and outstanding shares of the Company (excluding any treasury shares) as at the date of passing of this resolution.

About ZTO Express (Cayman) Inc.

ZTO Express (Cayman) Inc. (NYSE: ZTO and SEHK: 2057) (“ZTO” or the “Company”) is a leading and fast-growing express delivery company in China. ZTO provides express delivery service as well as other value-added logistics services through its extensive and reliable nationwide network coverage in China.

ZTO operates a highly scalable network partner model, which the Company believes is best suited to support the significant growth of e-commerce in China. The Company leverages its network partners to provide pickup and last-mile delivery services, while controlling the mission-critical line-haul transportation and sorting network within the express delivery service value chain.

For more information, please visit https://zto.investorroom.com.

Safe Harbor Statement

This announcement contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and other similar expressions. ZTO may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”) and The Stock Exchange of Hong Kong Limited (the “HKEX”), in its interim and annual reports to shareholders, in announcements, circulars or other publications made on the website of the HKEX, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including but not limited to statements about ZTO’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: risks relating to the development of the e-commerce and express delivery industries in China; its significant reliance on certain third-party e-commerce platforms; risks associated with its network partners and their employees and personnel; intense competition which could adversely affect the Company’s results of operations and market share; any service disruption of the Company’s sorting hubs or the outlets operated by its network partners or its technology system; ZTO’s ability to build its brand and withstand negative publicity, or other favorable government policies. Further information regarding these and other risks is included in ZTO’s filings with the SEC and the HKEX. All information provided in this announcement is as of the date of this announcement, and ZTO does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

ZTO Express (Cayman) Inc.

Investor Relations
E-mail: ir@zto.com
Phone: +86 21 5980 4508

SU Group Announces Distribution Agreement with Germany’s GEZE, Expanding Smart Building and Safety Technology Portfolio

By
Advertorial Desk
-

Agreement adds Globally Recognized Door, Window and Safety Technology Solutions to SU Group’s Integrated Security-Related Engineering Platform

HONG KONG, June 16, 2026 /PRNewswire/ — SU Group Holdings Limited (Nasdaq: SUGP) (“SU Group” or the “Company”), an integrated security-related engineering services company in Hong Kong, today announced a distributorship agreement with Germany’s GEZE, a multi-national manufacturer in innovative door, window and safety technology for Smart Buildings.

The agreement broadens SU Group’s product and solutions portfolio with GEZE’s extensive range of advanced building technologies, including automatic door systems, window technology, safety systems, smoke and heat extraction solutions, access control-related applications and building automation capabilities.

GEZE has been in the industry for over a century and has one of the industry’s most extensive product portfolios of smart building and safety technologies. This includes many award-winning products, popular for their innovative functions, high efficiency and clear focus on design, convenience and safety. GEZE’s portfolio is particularly relevant to the next generation of Smart Buildings, where doors, windows, safety systems and building management platforms are increasingly expected to work together. Its technologies help support controlled access, barrier-free movement, preventive fire protection, natural ventilation, smoke and heat extraction, energy efficiency and centralized monitoring.

SU Group’s Chairman and CEO, Dave Chan, said, “This is a big win for our customers, which put security at the forefront of planning and development decisions. The addition of GEZE to our product array will enable us to compete with top tier players, and participate in projects we could not have before, including those with the most advanced technological requirements. These technologies are increasingly important as developers, property owners and public-sector operators seek buildings that are not only secure, but also more accessible, efficient, connected and easier to manage.”

Key Takeaways

  • New distributorship agreement with GEZE, a German-headquartered global specialist in door, window and safety technology for Smart Buildings
  • Expands SU Group’s product offering into advanced automatic door systems, window technology, building automation, access control, fire protection and safety-related applications
  • Positions SU Group to pursue larger, more technically demanding projects across commercial properties, public facilities, infrastructure and residential developments
  • Strengthens SU Group’s ability to provide customers with integrated, end-to-end solutions that combine security engineering, safety, accessibility, convenience and smart building functionality
  • Adds a globally established brand founded in 1863, with deep expertise, international scale and a broad product portfolio focused on quality, design and innovation

About GEZE

GEZE is a German-headquartered, family-run technology company founded in 1863. The company develops and produces innovative door, window and safety technology for Smart Buildings and is recognized for its broad portfolio of products, systems and services. GEZE’s solutions support automatic door systems, window technology, smoke and heat extraction, safety technology, access control-related applications and building automation. With a global presence, more than 3,000 employees and subsidiaries across numerous international markets, GEZE combines engineering expertise, quality, design and digital connectivity to help create safer, more comfortable and more efficient buildings.

About SU Group Holdings Limited

SU Group (Nasdaq: SUGP) is an integrated security-related services company that primarily provides security-related engineering services, security guarding and screening services, and related vocational training services in Hong Kong. Through its subsidiaries, SU Group has been providing turnkey services to the existing infrastructure or planned development of its customers through the design, supply, installation, and maintenance of security systems for over two decades. The security systems that SU Group provides services include threat detection systems, traffic and pedestrian control systems, and extra-low voltage systems in private and public sectors, including commercial properties, public facilities, and residential properties in Hong Kong. For more information visit www.sugroup.com.hk.

Forward-Looking Statements

The Company makes forward-looking statements in this report within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties, including the closing of the offering, and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs.  These statements may be preceded by, followed by or include the words “may,” “might,” “will,” “will likely result,” “should,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “continue,” “target” or similar expressions. These forward-looking statements are based on information available to the Company as of the date of this report and involve substantial risks and uncertainties. Actual results may vary materially from those expressed or implied by the forward-looking statements herein due to a variety of factors, and other risks and uncertainties set forth in our reports filed with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update forward-looking statements as a result of new information, future events or developments or otherwise.

Beijing Tong Ren Tang brings Chinese medicine to life with the launch of “The Tong Ren Extraordinary Journey”, a school outreach programme designed for primary school students

By
Advertorial Desk
-

From campus-based learning to visits to a Chinese medicine production base, combining story-based learning with hands-on experience to bring students closer to TCM through fun and interactive engagement


HONG KONG SAR – Media OutReach Newswire – 16 June 2026 – Building on last year’s success, Beijing Tong Ren Tang’s “The Tong Ren Extraordinary Journey” school outreach programme has been further deepened and expanded this year. Evolving from in-school learning to a model that integrates and extends into off-campus activities, the programme combines school visits with tours of Beijing Tong Ren Tang’s production and R&D base, opening a new chapter in a comprehensive way and bringing students closer to traditional Chinese medicine (TCM) through a lively and interactive engagement.

Photo 1: "The Tong Ren Extraordinary Journey" visited 20 primary schools in Hong Kong, bringing students a fun and engaging introductory journey into the world of Chinese medicine.
Photo 1: “The Tong Ren Extraordinary Journey” visited 20 primary schools in Hong Kong, bringing students a fun and engaging introductory journey into the world of Chinese medicine.

Two-stage learning: from in-school education to hands-on experience
Through a variety of interactive formats, “The Tong Ren Extraordinary Journey” offers students an engaging and knowledge-rich introduction to Chinese medicine. Designed around the concept of “from understanding to experience,” the programme combines in-school learning with off-campus visits to Beijing Tong Ren Tang’s production and R&D base. Activities include guided storytelling on the “Tong Ren” story, acupoint-based interactive games, and lively introductions to Chinese medicine culture and basic Chinese medicine knowledge, making the learning experience both enjoyable and informative. Students can also visit Beijing Tong Ren Tang’s production and R&D base in Tai Po, where they tour the museum, learn about the operation of the production line, and explore the Chinese Herbal Garden. In this way, students gain a well-rounded understanding of Chinese medicine and learn how it can be applied in daily life.

Herbal planting activities reinforce learning experience
A special feature of the programme is a planting experience in the Beijing Tong Ren Tang Chinese Herbal Garden. Guided by gardeners and instructors, students take part in a seedling transplanting activity, observing herbal plants up close and experiencing the planting process first-hand. This hands-on experience not only gives them a sense of achievement but also deepens their understanding of what they have learned. Through this enjoyable and educational activity, Chinese medicine culture is brought to life for the younger generation while supporting its preservation and continued development.

Photos 2: Students visited the "Beijing Tong Ren Tang Chinese Herbal Garden" to learn about the characteristics and medicinal value of different Chinese herbs and took part in a hands-on planting activity.
Photos 2: Students visited the “Beijing Tong Ren Tang Chinese Herbal Garden” to learn about the characteristics and medicinal value of different Chinese herbs and took part in a hands-on planting activity.

In-school learning: “The Tong Ren Extraordinary Journey” tutorial
During the school visits under “The Tong Ren Extraordinary Journey,” Chinese medicine practitioners and instructors each led nearly 100 students at a time through a lively one-hour session, using an easy-to-understand approach that combined storytelling and interactive games to explore Chinese medicine knowledge. Topics covered ranged from itinerant physicians to hall physicians, from the acupuncture bronze figure to the meridian system, and from the four diagnostic methods of Chinese medicine to its internal and external treatment approaches. Students were also introduced to Tong Ren Tang’s history of supplying imperial medicine, as well as Chinese medicine concepts such as “monarch, minister, assistant and guide“. These sessions helped students understand Chinese medicine in an accessible way, while interactive acupoint games further strengthened memory and comprehension through play.

Off-campus experience: visits to Beijing Tong Ren Tang’s production and R&D base
After completing the school visit component of “The Tong Ren Extraordinary Journey,” students also had the opportunity to visit and experience Beijing Tong Ren Tang’s production and R&D base in Hong Kong. During the guided tour, students gained a deeper understanding of the story of Tong Ren Tang, a time-honoured Chinese medicine brand, its imperial medicine tradition and its pharmaceutical culture, while revisiting the core beliefs it upholds: “cultivating benevolence and virtue, and promoting health for the benefit of society” and its corporate motto of “No compromise on cost and labour despite the complexity of processing herbal medicine. No compromise on quality and standard despite the scarcity of medicine ingredients.”

During the visit, students sampled herbal tea as an entry point to understanding Chinese herbs. They then learned about the Chinese medicine production process and took part in a workshop on the traditional pill-rolling technique, an item of intangible cultural heritage. This allowed them to translate theory into practical experience, and to understand how herbs are processed and prepared into medicinal materials for use. Through this, they learned about the development of Chinese medicine from ancient times to the present, as well as the evolution of different dosage forms. Students later moved to the Beijing Tong Ren Tang Chinese Herbal Garden for a herbal planting activity, where they learned how soil, water and sunlight affect plant growth.

Expanded to 20 primary schools, with a comic book supporting school-based extended reading
This year, “The Tong Ren Extraordinary Journey” expanded to 20 primary schools, reaching approximately 3,000 teachers and students in total. To complement the in-school curriculum and extended reading, Beijing Tong Ren Tang specially wrote and produced the comic book The World of Chinese Medicine – “The Tong Ren Extraordinary Journey”. Featuring the adorable “Little Tong Ren” as the main character and guide, the comic adopts a child-friendly narrative approach to help students understand the meaning of “Tong Ren” and “Tong Ren Tang,” the wisdom of balance emphasised in Chinese medicine culture, and its people-oriented spirit of benevolence and compassionate healing. Beijing Tong Ren Tang hopes that, through more interesting and approachable content formats, Chinese medicine culture can take root on campus and, through students’ reading and sharing, extend into families and communities as a cultural learning journey that can be passed on continuously.

Bringing Chinese medicine into everyday life
Beijing Tong Ren Tang hopes to foster a relaxed and enjoyable learning environment for students, introducing Chinese medicine step by step and encouraging them to share what they have learned with family and friends. By starting from a child’s perspective and focusing on themes such as meridians, herbs and balance, the programme helps integrating the wisdom of TCM into students’ everyday knowledge systems and encouraging them to share and apply these insights in daily life.

Hashtag: #BeijingTongRenTang #TheTongRenExtraordinaryJourney #primaryschool #chinesemedicine


The issuer is solely responsible for the content of this announcement.

About Beijing Tong Ren Tang

Tong Ren Tang was founded in 1669 and has a 356-year history. The company has always adhered to its corporate motto of “No compromise on cost and labour despite the complexity of processing herbal medicine. No compromise on quality and standard despite the scarcity of medicine ingredients.” This commitment has led Beijing Tong Ren Tang to steady development, lasting through every generation, achieving excellence, and becoming a national treasure while expanding globally.

At the same time, Beijing Tong Ren Tang has taken on the mission of promoting traditional Chinese medicine culture, actively participating in domestic and international traditional Chinese medicine promotion activities, facilitating cultural exchanges around the world, and striving to expand the international influence of traditional Chinese medicine. To date, it has been operating over 160 retail branches in 26 countries and regions overseas, making it one of the most recognized traditional Chinese medicine brands internationally.

About Beijing Tong Ren Tang Chinese Medicine Company Limited

Established in Hong Kong in 2004, Beijing Tong Ren Tang Chinese Medicine Company Limited serves as Tong Ren Tang’s development platform outside Mainland China. The Company was listed on the Growth Enterprise Market of the Hong Kong Stock Exchange in 2013 and transferred to the Main Board in 2018. Guided by its corporate spirit of “cultivating benevolence and virtue, and promoting health for the benefit of society” and driven by its mission to “create health for all to share globally,” the Company has built on Hong Kong as its base while expanding its global presence. It is committed to promoting Chinese medicine culture beyond Mainland China, and has accelerated the internationalisation of Chinese medicine through a communication model that integrates medical services with pharmaceutical products and places culture at the forefront. (Beijing Tong Ren Tong Chinese Medicine Company Limited website: )

Magnus Carlsen Arrives in Hong Kong as the City Takes Centre Stage of the Chess World — for the First Time in History

By
Advertorial Desk
-

The world’s greatest player makes his Hong Kong debut alongside American star Fabiano Caruana, Mongolia’s 34th Prime Minister H.E. Mr Zandanshatar Gombojav, WR Chess founder Wadim Rosenstein, and special guest World Championship Challenger Javokhir Sindarov, opening the first East Asian edition of the FIDE World Team Rapid & Blitz Chess Championships and turning Hong Kong into the global capital of chess this week.


HONG KONG SAR – Media OutReach Newswire – 16 June 2026 – The greatest chess player of all time has touched down in Hong Kong. Magnus Carlsen, the Norwegian grandmaster and undisputed World No. 1, today made his first official appearance in the city, headlining a star-studded press conference at Rosewood Hong Kong, Gallery 304, just 24 hours before the opening move of the FIDE World Team Rapid & Blitz Chess Championships 2026 — the first time in history this prestigious global event is being staged in East Asia.

Magnus Carlsen (Left 2), five-time World Champion, answers questions from reporters at the WR Chess press conference in Hong Kong, 16 June 2026.
Magnus Carlsen (Left 2), five-time World Champion, answers questions from reporters at the WR Chess press conference in Hong Kong, 16 June 2026.

Carlsen took the stage alongside the sport’s most magnetic names — American grandmaster and former World Championship challenger Fabiano Caruana; Uzbek prodigy Javokhir Sindarov, the official Challenger in the upcoming World Championship match; and H.E. Mr Zandanshatar Gombojav, the 34th Prime Minister of Mongolia — all teammates on WR Chess, the German-founded super-team competing this week at Queen Elizabeth Stadium.

It is a line-up the chess world has never seen sit shoulder to shoulder on one stage. And it is happening in Hong Kong.


A Historic First for East Asia

From 17–21 June at Queen Elizabeth Stadium in Wan Chai, the FIDE World Team Rapid & Blitz Chess Championships 2026 bring together over 300 elite players from more than 50 countries, all chasing a share of a €500,000 prize fund — and the title of the strongest team on the planet across the sport’s two most thrilling formats.

It is the first time the championship has ever been held in East Asia, an inflection point that places Hong Kong squarely at the centre of the global chess calendar and underscores the city’s standing as Asia’s premier host of world-class sporting and intellectual spectacle.

A Founder Who Plays His Own Game
The afternoon’s quietly extraordinary character was Wadim Rosenstein, the 35-year-old German entrepreneur behind WR Chess and Chairman of WR Group Holding, one of the fastest-rising private holding groups in the world. Having committed millions of euros of his personal wealth to elevating chess globally, Rosenstein is doing something almost unheard of at this level: he is playing himself, taking the U2000 board for WR Chess this week alongside Carlsen, Caruana, Sindarov, and H.E. Mr Zandanshatar Gombojav.

Wadim Rosenstein, Chairman of WR Group Holding, speaks during the WR Chess press conference in Hong Kong, 16 June 2026.
Wadim Rosenstein, Chairman of WR Group Holding, speaks during the WR Chess press conference in Hong Kong, 16 June 2026.

It is the kind of move that captures the spirit of WR Chess in a single gesture — world champions and a dedicated enthusiast, all in the same uniform, all under the same banner.

Headlines from the Press Conference

  • A historic first — Hong Kong becomes the first East Asian city ever to host the FIDE World Team Rapid & Blitz Chess Championships
  • A first visit — Magnus Carlsen makes his official Hong Kong debut
  • A homecoming — Ella Carlsen returns to the city of her birth
  • Four giants, one stage — Carlsen, Caruana, Sindarov, and H.E. Mr Zandanshatar address the world’s media side by side
  • A head of state at the board — Mongolia’s 34th Prime Minister, H.E. Mr Zandanshatar Gombojav, competes alongside the world’s elite
  • A founder who plays — Wadim Rosenstein takes the U2000 seat for his own team

The WR Chess Roster — Ten Names, One Banner
WR Chess arrives in Hong Kong with a line-up few teams in the history of the sport could rival — current and former World Champions, World Championship challengers, a serving statesman, and the founder himself at the amateur board.

H.E. Mr Zandanshatar Gombojav (Left 1), the 34th Prime Minister of Mongolia, attends the WR Chess press conference in Hong Kong, 16 June 2026.
H.E. Mr Zandanshatar Gombojav (Left 1), the 34th Prime Minister of Mongolia, attends the WR Chess press conference in Hong Kong, 16 June 2026.

Magnus Carlsen (Norway) — World No. 1 and the most dominant chess player in modern history. Five-time World Champion, multi-time World Rapid and World Blitz Champion, and the highest-rated player to ever sit at a board.

Fabiano Caruana (USA) — The man who pushed Carlsen to twelve straight draws in the 2018 World Championship final and remains a permanent fixture at the very top of the world rankings. The strongest American grandmaster of his generation.

Wesley So (USA) — Fischer Random World Champion and three-time U.S. Champion, celebrated for a positional clarity few in the world can match. One of the most respected technical players on tour.

Maxime Vachier-Lagrave (France) — Former World Blitz Champion and one of the most feared attacking minds in elite chess. France’s standard-bearer at the top board for more than a decade.

Jan-Krzysztof Duda (Poland) — Chess World Cup winner and the player who famously ended Magnus Carlsen’s record-breaking 125-game unbeaten streak in classical chess. Poland’s first true superstar of the modern era.

Alexandra Kosteniuk (Switzerland) — Former Women’s World Champion and one of the most recognisable ambassadors the game has ever produced. A grandmaster whose career has spanned three decades at the top.

Alexandra Goryachkina (Russia) — Women’s World Championship challenger and one of the most consistent forces in elite women’s chess. A grandmaster known for an iron will and ferocious end-game technique.

H.E. Mr Zandanshatar Gombojav (Mongolia) — The 34th Prime Minister of Mongolia and a passionate competitive player, bringing the gravitas of statecraft to the board and underscoring chess’s reach into the highest corridors of public life.

Wadim Rosenstein (Germany) — Team founder, Chairman of WR Group Holding, and one of the most committed private patrons in modern chess. This week, he occupies the U2000 board himself — the rarest sight in elite team chess.

Jan Gustafsson (Germany) — Team Captain. Grandmaster, longtime second to Magnus Carlsen in multiple World Championship matches, and one of the most respected strategic minds and broadcasters in the game.

(From left) Alexandra Goryachkina, Jan-Krzysztof Duda, Jan Gustafsson, H.E. Mr Zandanshatar Gombojav, Magnus Carlsen, Wadim Rosenstein, Fabiano Caruana, special guest Javokhir Sindarov, Maxime Vachier-Lagrave, and Alexandra Kosteniuk during the WR Chess' team press conference in Hong Kong, 16 June 2026.
(From left) Alexandra Goryachkina, Jan-Krzysztof Duda, Jan Gustafsson, H.E. Mr Zandanshatar Gombojav, Magnus Carlsen, Wadim Rosenstein, Fabiano Caruana, special guest Javokhir Sindarov, Maxime Vachier-Lagrave, and Alexandra Kosteniuk during the WR Chess’ team press conference in Hong Kong, 16 June 2026.


What’s Next

Play begins tomorrow, 17 June, at Queen Elizabeth Stadium, Wan Chai, with the world’s strongest clubs and federations clashing across rapid and blitz formats through 21 June. WR Chess will field its full line-up from Round 1.

Hashtag: #WRChess

The issuer is solely responsible for the content of this announcement.

WR Chess

WR Chess is the elite club team founded by German entrepreneur Wadim Rosenstein under the WR Group Holding umbrella. Built to showcase the best minds in modern chess, the team unites reigning world-class grandmasters, rising prodigies, and global public figures under one banner — and competes at the world’s premier rapid and blitz events.

FIDE World Team Rapid & Blitz Chess Championships 2026

Sanctioned by the International Chess Federation (FIDE), the World Team Rapid & Blitz Championships gather the strongest chess clubs and federations on the planet for two of the sport’s most electrifying formats. The 2026 edition, held in Hong Kong from 17–21 June at Queen Elizabeth Stadium, features over 300 players from 50+ countries competing for a €500,000 prize fund.

PERKESO and 7-Eleven Malaysia Partner to Support Return-To-Work Employment Pathways Nationwide

By
Advertorial Desk
-

Collaboration will provide PERKESO Return to Work participants with training, workplace exposure and potential employment opportunities across 7-Eleven Malaysia’s retail network.


MERU, PERAK – Media OutReach Newswire – 16 June 2026 – Pertubuhan Keselamatan Sosial (PERKESO) and 7-Eleven Malaysia today formalised a strategic partnership through the signing of a Memorandum of Understanding (MOU) aimed at supporting the rehabilitation, employability, and workforce reintegration of PERKESO-insured persons under the Return to Work (RTW) Programme.

From Left to Right: Datuk Dr. Hafez Bin Hussain, Executive Director of PERKESO Rehabilitation Centre, Dato' Sri Dr. Mohammed Azman bin Aziz Mohammed, Group CEO of PERKESO, Dato' Sri Subahan bin Kamal, Chairman of PERKESO, Tan Sri Dato' Seri Mohd Annuar bin Zaini, Chairman of 7-Eleven Holdings Berhad, Mr Wong Wai Keong, Executive Director cum Co-CEO of 7-Eleven Sdn. Bhd. and Mr Aaron Ng, Chief Operations Officer of 7-Eleven Sdn. Bhd.
From Left to Right: Datuk Dr. Hafez Bin Hussain, Executive Director of PERKESO Rehabilitation Centre, Dato’ Sri Dr. Mohammed Azman bin Aziz Mohammed, Group CEO of PERKESO, Dato’ Sri Subahan bin Kamal, Chairman of PERKESO, Tan Sri Dato’ Seri Mohd Annuar bin Zaini, Chairman of 7-Eleven Holdings Berhad, Mr Wong Wai Keong, Executive Director cum Co-CEO of 7-Eleven Sdn. Bhd. and Mr Aaron Ng, Chief Operations Officer of 7-Eleven Sdn. Bhd.

The collaboration will provide RTW participants with access to pre-employment training, practical workplace exposure, workforce readiness initiatives, and potential employment opportunities within 7-Eleven Malaysia’s retail operations.

As Malaysia’s largest convenience store chain with more than 2,700 stores nationwide, 7-Eleven Malaysia is uniquely positioned to offer accessible employment and training opportunities within local communities across the country. The company’s extensive footprint enables programme participants to benefit from opportunities closer to home, reducing barriers to workforce participation while providing a familiar and supportive working environment.

The MOU signing ceremony was held at the Pusat Rehabilitasi Neuro-Robotik dan Sibernik Kebangsaan PERKESO (PRNRSKP) in Meru, Perak, and was attended by senior representatives from both organisations.

Speaking at the event, Tan Sri Dato’ Seri Mohd Annuar bin Zaini, Chairman of 7-Eleven Malaysia Holdings Berhad, said employment plays a critical role in helping individuals regain confidence, independence, and a renewed sense of purpose following rehabilitation.

“Recovery is not only about regaining physical strength. It is also about restoring confidence, dignity and the opportunity to participate meaningfully in society once again. Through this collaboration with PERKESO, we hope to create pathways for individuals to

rebuild their lives through employment and demonstrate that every worker deserves the opportunity for a second chance.

At 7-Eleven Malaysia, giving back to the community is not simply a corporate responsibility. It is a commitment to creating meaningful impact where we can. We are honoured to work alongside PERKESO in helping individuals transition from recovery to employment, enabling them to regain their independence and contribute meaningfully to society once again.”

Under the collaboration, PERKESO RTW participants will have access to pre-employment training programmes, practical workplace exposure, workforce readiness initiatives and potential employment opportunities within 7-Eleven Malaysia’s retail operations. Participants will gain hands-on experience in customer service, product management and daily retail operations, equipping them with practical skills that can support long-term career development and employability.

7-Eleven Malaysia is committed to providing a safe, inclusive, and supportive workplace environment throughout the programme. Participants will receive onboarding, workplace guidance, supervision and ongoing support during their placement journey, in close collaboration with PERKESO.

The initiative is designed to provide more than short-term workplace exposure. By offering real-world experience and structured employment pathways, both organisations aim to create sustainable opportunities that support long-term self-sufficiency and economic participation.

The partnership reflects a shared commitment to ensuring that Malaysians who have experienced workplace injuries or health setbacks are given meaningful opportunities to rebuild their lives through employment. By combining PERKESO’s rehabilitation expertise with 7-Eleven Malaysia’s extensive nationwide retail network, the partnership seeks to bridge the gap between recovery and sustainable employment.

The partnership also demonstrates the important role that public-private collaboration can play in strengthening Malaysia’s social protection ecosystem while increasing workforce participation among individuals recovering from workplace injuries or health-related challenges.

This marks the first formal employment-focused collaboration between PERKESO and 7-Eleven Malaysia. Both parties aim to welcome the first cohort of RTW participants before the end of 2026, with plans to progressively expand the programme to additional locations and participants nationwide.

Through this collaboration, PERKESO and 7-Eleven Malaysia reaffirm their shared belief that every Malaysian deserves the opportunity to rebuild, recover and contribute meaningfully to society, and that no worker should be left behind following a workplace injury or setback.
Hashtag: #7ElevenMalaysia

The issuer is solely responsible for the content of this announcement.

About 7-Eleven Malaysia

7-Eleven Malaysia Holdings Berhad through its subsidiary 7-Eleven Malaysia Sdn. Bhd. is the owner and operator of 7-Eleven stores in Malaysia. Incorporated on 4 June 1984, 7-Eleven Malaysia has made its mark in the retailing scene and has been a prominent icon for over 40 years. 7-Eleven Malaysia is the pioneer and largest 24-hour standalone convenience store operator in Malaysia with over 2,700 outlets nationwide and serves more than 1 million customers daily. 7-Eleven stores can be found across bustling commercial districts to serene suburban residential compounds throughout Malaysia, from petrol stations and LRT stations to shopping malls and medical institutions. My7E loyalty app boasted an impressive membership of 3.6 million users. As we forge ahead, our commitment remains steadfast in enriching the experience for our valued members, offering an array of rewards that enhance their journey as My7E enthusiasts. 7-Eleven is Always There For You. To learn more, please visit our website at

1...296297298...6,527Page 297 of 6,527